Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2023

Trial of Solanezumab in Preclinical Alzheimer’s Disease

In a phase 3 trial involving 1169 participants with preclinical Alzheimer’s disease, solanezumab did not slow cognitive decline over 240 weeks compared to placebo, despite a reduction in amyloid burden.
R. Sperling; M. Donohue; R. Raman; M. Rafii; Keith A. Johnson; C. Masters; C. van Dyck; T. Iwatsubo; G. Marshall; R. Yaari; M. Mancini; K. Holdridge; M. Case; J. Sims; P. Aisen· New England Journal of Medicine· 2023· DOI 10.1056/NEJMoa2305032

The core problem

Alzheimer’s disease (AD) is characterized by progressive cognitive decline and the accumulation of amyloid-beta (Aβ) plaques in the brain. Monoclonal antibodies targeting various forms of amyloid have been tested at different stages of the disease with mixed results. Solanezumab is a monoclonal antibody that specifically targets monomeric amyloid. The objective of this phase 3 trial was to evaluate the efficacy and safety of solanezumab in persons with preclinical Alzheimer’s disease, defined as individuals with elevated brain amyloid levels but no cognitive impairment. The study aimed to determine whether early intervention with solanezumab could slow cognitive decline.

Innovation

The trial enrolled persons aged 65 to 85 years with a global Clinical Dementia Rating (CDR) score of 0 (indicating no cognitive impairment), a Mini–Mental State Examination (MMSE) score of 25 or higher (range 0–30, with lower scores indicating poorer cognition), and elevated brain amyloid levels as assessed by 18F-florbetapir positron-emission tomography (PET). Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 mg intravenously every 4 weeks or placebo. The primary end point was the change in the Preclinical Alzheimer Cognitive Composite (PACC) score over a period of 240 weeks. The PACC score is calculated as the sum of four z scores, with higher scores indicating better cognitive performance. The trial was funded by the National Institute on Aging and others (A4 ClinicalTrials.gov number, NCT02008357).
Introduction
Alzheimer’s disease (AD) is characterized by progressive cognitive decline and the accumulation of amyloid-beta (Aβ) plaques in the brain. Monoclonal antibodies targeting various forms of amyloid have been tested at different stages of the disease with mixed results. Solanezumab is a monoclonal antibody that specifically targets monomeric amyloid. The objective of this phase 3 trial was to evaluate the efficacy and safety of solanezumab in persons with preclinical Alzheimer’s disease, defined as individuals with elevated brain amyloid levels but no cognitive impairment. The study aimed to determine whether early intervention with solanezumab could slow cognitive decline.

Why it matters

The results of this phase 3 trial indicate that solanezumab, which targets monomeric amyloid, did not slow cognitive decline compared with placebo over 240 weeks in persons with preclinical Alzheimer’s disease. Although solanezumab reduced amyloid accumulation as measured by PET (mean increase of 11.6 centiloids vs. 19.3 centiloids with placebo), this did not translate into a cognitive benefit. The difference in PACC score change (−0.30; 95% CI, −0.82 to 0.22; P = 0.26) was not statistically significant. The safety profile was generally consistent with previous studies of anti-amyloid antibodies, with ARIA with edema occurring in less than 1% of participants in both groups and ARIA with microhemorrhage or hemosiderosis occurring in similar proportions (29.2% vs. 32.8%). These findings suggest that targeting monomeric amyloid may not be sufficient to slow cognitive decline in preclinical AD, and that other forms of amyloid or alternative therapeutic strategies may be needed. The trial’s large sample size and long follow-up period strengthen the validity of these conclusions.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…